Ono Pharmaceutical Co (Ono Pharmaceutical Co) Interest Expense : $-8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ono Pharmaceutical Co's interest expense for the three months ended in Mar. 2024 was $ 2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ono Pharmaceutical Co's Operating Income for the three months ended in Mar. 2024 was $ 102 Mil. Ono Pharmaceutical Co's Interest Expense for the three months ended in Mar. 2024 was $ 2 Mil. Ono Pharmaceutical Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ono Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Ono Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Interest Expense Chart

Ono Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-7.85

-1.26

-7.37

-6.83

-1.53

Ono Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-2.16	-1.71	-0.14	-7.68	1.53

Ono Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8 Mil.

Ono Pharmaceutical Co (OTCPK:OPHLY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ono Pharmaceutical Co's Interest Expense for the three months ended in Mar. 2024 was $2 Mil. Its Operating Income for the three months ended in Mar. 2024 was $102 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $44 Mil.

Ono Pharmaceutical Co's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Ono Pharmaceutical Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

OPHLF:USA 4528:Japan ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines

From GuruFocus

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

By PRNewswire • 12-01-2023

Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report

By Holly LaFon Holly LaFon • 05-13-2016

Ono Pharmaceutical Co Stock Appears To Be Modestly Undervalued

By GF Value • 07-05-2021

T. Rowe Price Japan Fund Purchases 5 Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-18-2017